Quick Answer
AN2 Therapeutics, Inc. reported Common Stock Shares Outstanding of 27.41 million shares for the year ending 2025.
- AN2 Therapeutics, Inc. showed a decrease of -8.4% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from AN2 Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: 18.71 million shares | Q2 2022: 19.40 million shares | Q3 2022: 19.40 million shares | Q1 2023: 19.43 million shares | Q2 2023: 21.93 million shares | Q3 2023: 29.74 million shares | Q1 2024: 29.82 million shares | Q2 2024: 29.83 million shares | Q3 2024: 29.87 million shares | Q1 2025: 30.14 million shares | Q2 2025: 27.38 million shares | Q3 2025: 27.37 million shares.
- Over the full 5 years of available data (2021 to 2025), AN2 Therapeutics, Inc.'s Common Stock Shares Outstanding has grown by 904.0%.
- Historical annual values: Fiscal year 2025: 27.41 million shares | Fiscal year 2024: 29.92 million shares | Fiscal year 2023: 29.74 million shares | Fiscal year 2022: 19.40 million shares | Fiscal year 2021: 2.73 million shares.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: